Pernix Therapeutics Buys Orexigen’s Contrave for $73.5Mn

 Pernix Therapeutics Buys Orexigen’s Contrave for $73.5Mn

Pernix Therapeutics Buys Orexigen’s Contrave for $73.5Mn

Shots:
  •  Nalpropion buys global commercialization rights of Orexigen’s Contrave a weight loss drug. Nalpropion is an investor group which includes Pernix
  •  Contrave has approx. 2.5 Mn prescription since 2014, presently, it is launched in 25 countries with expected launch in 13 countries in 2018 and has an US exclusivity till 2030
  • Pernix will have an option to acquire either upto 49.9 % of Nalpropion or wholly a special purpose entity

Click here to read full press release/ article | Ref:  Pernixtx | Image: LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post